GlassScriptPhysician profile
Eboni X Carter
NPI 1427021724
$1,451.14
in general payments reported to CMS, 2019-2025
19 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $72.24 · 2021: $211 · 2022: $386 · 2023: $241 · 2024: $151 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586 · Education: $45.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.26 |
| Education | $45.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $545.10 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $432.65 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $90.65 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $46.44 | 2021-2023 | Watchman Flx |
| Dexcom, INC. | $39.25 | 2024-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $33.18 | 2024-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $31.23 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $29.17 | 2019 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Exact Sciences Corporation | $23.67 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.14 | 2019 | |
| Bausch Health US, LLC | $19.03 | 2021 | |
| Amgen INC. | $18.14 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.67 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.85 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.45 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $15.49 | 2019 | |
| Glaxosmithkline, LLC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eboni Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.